Agios Reports Fourth Quarter and Full Year 2017 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. LRCX
6. LVS
7. SAP
8. CSX
9. SPY
10. KNX

Go back to Agios Reports Fourth Quarter and Full Year 2017 Financial Results

Agios Pharma (AGIO) PT Raised to $80 at Credit Suisse; 'Platform opportunities beyond IDH'

February 15, 2018 8:59 AM EST

Credit Suisse raised its price target on Agios Pharma (NASDAQ: AGIO) to $80.00 (from $66.00) while maintaining a Outperform rating.

... More

Agios Pharma (AGIO) PT Raised to $86 at Needham & Company; 'Continued Execution'

February 14, 2018 12:48 PM EST

Needham & Company raised its price target on Agios Pharma (NASDAQ: AGIO) to $86.00 (from $72.00) while maintaining a Buy rating.

Analyst Chad Messer commented, " Agios made broad progress across its growing pipeline in 2017 and we expect another busy year with their 2nd drug launch and... More

Agios Pharma (AGIO) Misses Q4 EPS by 15c

February 14, 2018 7:08 AM EST

Agios Pharma (NASDAQ: AGIO) reported Q4 EPS of ($1.81), $0.15 worse than the analyst estimate of ($1.66). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $13.34 million.

For earnings history and earnings-related data on Agios Pharma (AGIO) click here.

... More